ACA Category Banner

Compliance

This section focuses on health care compliance and regulations – both national and state – including the ACA. It includes changes in health care law, regulation, and court decisions and their impact on health insurance professionals, employers, and individuals.

More Plans, Carriers, Savings Available During Open Enrollment

Open enrollment began Monday on NevadaHealthLink.com, the online health insurance marketplace operated by the Silver State Health Insurance Exchange, which connects Nevadans to affordable health and dental plans.

Read More

Average Family Premiums Rose 4% This Year To $22K Due To Healthcare Use Decline: KFF

The annual family premiums for employer-sponsored health plans increased by 4% in 2021 to an average of $22,221 as the COVID-19 pandemic blunted massive premium hikes, a new survey finds. The Kaiser Family Foundation released its 2021 employer health benefits survey Wednesday, which explored the employer benefits and cost-sharing offered for plans. The survey also found more ...

Read More

Update On COBRA Premium Payments During Ongoing Covid-19 “Outbreak Period”

The COVID-19 pandemic brought changes to many health insurance related items; one of the biggest changes was to federal COBRA administration. COBRA, which allows a person to continue group health coverage upon loss of eligibility for that coverage, normally requires a person to make COBRA elections and initial premium payments within short timeframes – 60 ...

Read More

Researcher: Medicare Advantage Plans Costing Billions More Than They Should

Switching seniors to Medicare Advantage plans has cost taxpayers tens of billions of dollars more than keeping them in original Medicare, a cost that has exploded since 2018 and is likely to rise even higher, new research has found. Richard Kronick, a former federal health policy researcher and a professor at the University of California-San ...

Read More

U.S. Postal Service Warns Vaccine Rules Could Affect Deliveries

The U.S. Postal Service raised concerns on Wednesday that the Biden administration’s new rules requiring large employers to require vaccinations or weekly COVID-19 testing could result in “high levels of absenteeism” and affect deliveries. Last week, the Labor Department issued rules that require businesses with 100 or more employees to mandate weekly testing or vaccines by Jan. ...

Read More

Retail And Trucking Trade Groups Sue Biden Administration To Overturn Vaccine Mandate

National industry groups representing retail, truckers and independent businesses sued the Biden administration Wednesday over its vaccine and testing requirements for private companies, claiming they would cause “irreparable harm.” The National Retail Federation, the National Federation of Independent Business and the American Trucking Associations, told the U.S. Court of Appeals for the 5th Circuit in ...

Read More

Real Medicare Drug Savings In Dems’ Bill — But Not Overnight

Medicare enrollees who take expensive medicines could save thousands of dollars a year under the Democrats’ sweeping social agenda bill, but those dividends won’t come overnight. Instead, they’ll build gradually over the decade. Unveiled late last week, the bill’s Medicare prescription drug compromise barely survived a pharmaceutical industry lobbying blitz. Experts who’ve analyzed the complex ...

Read More

Appeals Court Halts COVID Vaccine Mandate For Larger Businesses

A federal appeals court on Saturday temporarily halted the Biden administration's COVID-19 vaccine requirement for businesses with 100 or more workers.

Read More

‘A Massive Step Forward’: Democrats Clinch Drug Pricing Deal

Democrats on Tuesday announced an agreement on drug pricing reform, coming out in favor of allowing Medicare Part D to negotiate directly with pharmaceutical companies for the first time since its creation, a move the drug industry has fought for nearly two decades.

Read More

Democrats’ Drug Pricing Deal Is ‘Not A Bad Outcome’ For Pharma, Analysts Write

The pharmaceutical industry has strongly resisted some of the proposals presented in the years-long drug pricing brouhaha, and the final result is "not a bad outcome" for drugmakers, one team of analysts recently stated.

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square